1-cyclobutyl-methyl chloroformate | 81228-88-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 1-cyclobutyl-methyl chloroformate
• 英文别名: cyclobutylmethyl carbonochloridate；Cyclobutylmethyl chloroformate
• CAS: 81228-88-8
• 化学式: C₆H₉ClO₂
• 分子量: 148.589
• InChiKey: VYDCMCUZQPGSKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)-6-(1,2,3,6-tetrahydropyridin-4-yl)benzo[d]thiazole 、 1-cyclobutyl-methyl chloroformate 在 水 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以84%的产率得到cyclobutylmethyl 4-(2-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)benzo[d]thiazol-6-yl)-5,6-dihydropyridine-1(2H)-carboxylate
  参考文献：
  名称：

  [EN] BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS
  [FR] COMPOSÉS HÉTÉROARYLES BICYCLIQUES EN TANT QUE MODULATEURS DE GPR119

  摘要：

  结构式I的新化合物：或其对映体、二对映体、互变异构体、前药或盐，其中A、D、Di、E、J、L、n、Q、R2和R4在此处被定义，提供了这些化合物是GPR119 G蛋白偶联受体调节剂。GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病的进展方面是有用的。因此，本公开还涉及包含这些新化合物的组合物和使用任何这些新化合物或包含任何这些新化合物的组合物治疗与GPR119 G蛋白偶联受体活性相关的疾病或症状的方法。

  公开号：

  WO2011140160A1

文献信息

• BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS
  申请人：Ye Xiang-Yang

  公开号：US20130053345A1

  公开（公告）日：2013-02-28

  Novel compounds of structure Formula I: or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein A, D, Di, E, J, L, n, Q, R 2 and R 4 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

  提供了结构式I的新化合物，或其对映体、顺反异构体、互变异构体、前药或盐，其中A、D、Di、E、J、L、n、Q、R2和R4在此定义，这些化合物是GPR119 G蛋白偶联受体调节剂。 GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病方面是有用的。因此，本公开还涉及包含这些新化合物的组合物以及使用任何这些新化合物或包含任何这些新化合物的组合物来治疗与GPR119 G蛋白偶联受体活性相关的疾病或病症的方法。
• FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USERS THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP3431471A1

  公开（公告）日：2019-01-23

  Provided are a compound represented by formula I, a raceme thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof, a preparation method therefor, a pharmaceutical composition comprising the compound, and uses thereof serving as an lysine specific demethylase 1 (LSD1) inhibitor. Provided are uses of the fluorinated cyclopropylamine compound represented by formula I in the treatment of cancers.

  提供一种由式 I 代表的化合物、其外消旋体、其 R-异构体、其 S-异构体、其药用盐和其混合物、其制备方法、包含该化合物的药物组合物以及其作为赖氨酸特异性去甲基化酶 1（LSD1）抑制剂的用途。提供了式 I 所代表的氟化环丙胺化合物在治疗癌症中的用途。
• Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US10836743B2

  公开（公告）日：2020-11-17

  Provided is a fluorinated cyclopropylamine compound represented by formula I, a racemate thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof. Also provided are pharmaceutical compositions containing the compound, a preparation method for the compound, and uses thereof as a lysine specific demethylase 1 (LSD1) inhibitor, and in the treatment of cancers.

  本发明提供了一种由式 I 代表的氟化环丙胺化合物、其外消旋体、其 R-异构体、其 S-异构体、其药用盐以及其混合物。还提供了含有该化合物的药物组合物、该化合物的制备方法，以及其作为赖氨酸特异性去甲基化酶 1（LSD1）抑制剂和治疗癌症的用途。
• BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2566860A1

  公开（公告）日：2013-03-13
• ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20080125444A1

  公开（公告）日：2008-05-29

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.